Advertisement
New Zealand markets open in 8 hours 13 minutes

  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     

  • NZD/USD

    0.5932
    -0.0005 (-0.08%)
     

  • NZD/EUR

    0.5541
    -0.0005 (-0.09%)
     

  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     

  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     

  • OIL

    82.64
    -0.17 (-0.21%)
     

  • GOLD

    2,331.60
    -6.80 (-0.29%)
     

  • NASDAQ

    17,245.60
    -281.20 (-1.60%)
     

  • FTSE

    8,057.30
    +16.92 (+0.21%)
     

  • Dow Jones

    37,892.01
    -568.91 (-1.48%)
     

  • DAX

    17,856.46
    -232.24 (-1.28%)
     

  • Hang Seng

    17,284.54
    +83.27 (+0.48%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • NZD/JPY

    92.2590
    +0.1440 (+0.16%)
     

CooperCompanies Announces Release Date for Third Quarter 2022

The Cooper Companies, Inc.
·1-min read
The Cooper Companies, Inc.
The Cooper Companies, Inc.

SAN RAMON, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- CooperCompanies (NYSE: COO) today announced it will release third quarter 2022 financial results on Wednesday, August 31, 2022, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments.

To participate in the call please follow this link to register and receive the dial-in information. A simultaneous webcast of the call will be available through the “Investor Relations” section of the CooperCompanies website at http://investor.coopercos.com. A replay of the webcast will be available approximately two hours following the event.

About CooperCompanies
CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE: COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, CA, Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visit www.coopercos.com.

Contact:
Kim Duncan
Vice President, Investor Relations and Risk Management
925-460-3663
ir@cooperco.com